Medicines · devices · diagnostics
Product portfolio
Browse development presentations by generic name, dosage form, record type, category or portfolio reference. Trade names and final packaging are not published.
Public development records16 categories
178
Record by record.
Generic identities and proposed presentations, with evidence boundaries kept visible.
168 medicine records · 10 device or diagnostic records · 178 evidence-layer dossiers
- Portfolio scope
- 178 public recordsComputed from the current catalogue
- Medicine records
- 168Generic development identities
- Device / diagnostic records
- 10Separate evidence requirements
- Commercial availability
- Not marketedNo current Luang Pharma supply
01 · Reading the portfolio
Identity, presentation and approval are different fields.
Portfolio status
These records do not establish product approval or availability. A proposed presentation is not a specification, approved label or offer of supply. The portfolio includes dosage forms beyond the initial planned production modules. Evidence-layer integration is an editorial implementation status, not clinical or regulatory approval.
No Luang Pharma product is on the market. A medicine offered under the company’s name is not its product: read the notice and report it.
- Generic identity
- The name or device type used to identify a public record.
- Proposed presentation
- Recorded form, strength and pack. Unresolved relationships are kept explicit.
- Manufacturing route
- Not established by portfolio inclusion; records extend beyond the initial Boten modules.
- Approval & availability
- Require separate product- and market-specific evidence.
02 · Category register
Explore the public records.
16 portfolio categories. Select a category to reveal its records. The record count is not a product-approval or manufacturing count.
Representative record · LP-002
Paracetamol Tablets
Two proposed strengths. Pack mapping and release characteristics remain unresolved.
Showing 178 of 178 records
Portfolio records
Anti-Infectives25 public records
| Record | Dosage form / type | Proposed strength / configuration | Proposed pack | Status |
|---|---|---|---|---|
| Acyclovir TabletsLP-023 | TabletMedicine | 200 mg; 400 mg; 800 mg | Blister 10 x 10 tablets | Development record |
| Albendazole Chewable tabletLP-020 | Chewable tabletMedicine | 200 mg; 400 mg | Blister or bottle | Development record |
| Amoxicillin + clavulanic acid TabletsLP-025 | TabletMedicine | 500 mg + 125 mg; 875 mg + 125 mg | Blister 2 x 7 or 10 tablets | Development record |
| Amoxicillin CapsulesLP-024 | CapsuleMedicine | 250 mg; 500 mg | Blister 10 x 10 capsules | Development record |
| Artemether + lumefantrine Tablet/dispersible tabletLP-026 | Tablet/dispersible tabletMedicine | 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet | Blister pack; adult 6-dose pack and paediatric dispersible pack per national malaria protocol | Development record |
| Azithromycin TabletsLP-027 | TabletMedicine | 250 mg; 500 mg | Blister 3 or 6 tablets | Development record |
| Cefalexin CapsulesLP-028 | CapsuleMedicine | 250 mg; 500 mg | Blister 10 x 10 capsules | Development record |
| Cefixime TabletsLP-029 | TabletMedicine | 200 mg; 400 mg | Blister 1 x 10 tablets | Development record |
| Chloramphenicol Eye dropsLP-030 | Eye dropsMedicine | 0.5% | Dropper bottle 5 mL / 10 mL | Development record |
| Chloramphenicol Eye ointmentLP-031 | Eye ointmentMedicine | 1% | Tube 5 g | Development record |
| Ciprofloxacin ophthalmic Eye dropsLP-033 | Eye dropsMedicine | 0.3% | Dropper bottle 5 mL | Development record |
| Ciprofloxacin TabletsLP-032 | TabletMedicine | 250 mg; 500 mg | Blister 10 x 10 tablets | Development record |
| Cloxacillin CapsulesLP-034 | CapsuleMedicine | 250 mg; 500 mg | Blister 10 x 10 capsules | Development record |
| Doxycycline CapsulesLP-035 | CapsuleMedicine | 100 mg | Blister 10 x 10 capsules | Development record |
| Erythromycin TabletsLP-036 | TabletMedicine | 250 mg; 500 mg | Blister 10 x 10 tablets | Development record |
| Fluconazole CapsulesLP-037 | CapsuleMedicine | 50 mg; 150 mg; 200 mg | Blister 1, 4 or 10 capsules | Development record |
| Mebendazole TabletsLP-021 | TabletMedicine | 100 mg; 500 mg | Blister or bottle | Development record |
| Metronidazole TabletsLP-038 | TabletMedicine | 200 mg; 400 mg; 500 mg | Blister 10 x 10 tablets | Development record |
| Nitrofurantoin CapsulesLP-039 | CapsuleMedicine | 50 mg; 100 mg | Blister 10 x 10 capsules | Development record |
| Nystatin Oral dropsLP-022 | Oral dropsMedicine | 100,000 IU/mL | Bottle 30 mL | Development record |
| Ofloxacin Ear dropsLP-223 | Ear dropsMedicine | 0.3% | Dropper bottle 5 mL | Development record |
| Ofloxacin Eye dropsLP-040 | Eye dropsMedicine | 0.3% | Dropper bottle 5 mL | Development record |
| Praziquantel TabletsLP-041 | TabletMedicine | 600 mg | Blister 6 tablets | Development record |
| Sulfamethoxazole + Trimethoprim TabletsLP-042 | TabletMedicine | 400 mg + 80 mg; 800 mg + 160 mg | Blister 10 x 10 tablets | Development record |
| Tetracycline Eye ointmentLP-043 | Eye ointmentMedicine | 1% | Tube 5 g | Development record |
Cardiovascular Medicines14 public records
| Record | Dosage form / type | Proposed strength / configuration | Proposed pack | Status |
|---|---|---|---|---|
| Acetylsalicylic acid TabletsLP-044 | TabletMedicine | 81 mg; 100 mg; 250 mg | Blister 10 x 10 tablets | Development record |
| Amlodipine TabletsLP-045 | TabletMedicine | 5 mg; 10 mg | Blister 10 x 10 tablets | Development record |
| Atenolol TabletsLP-046 | TabletMedicine | 50 mg; 100 mg | Blister 10 x 10 tablets | Development record |
| Atorvastatin TabletsLP-047 | TabletMedicine | 10 mg; 20 mg; 40 mg | Blister 10 x 10 tablets | Development record |
| Bisoprolol TabletsLP-048 | TabletMedicine | 2.5 mg; 5 mg; 10 mg | Blister 10 x 10 tablets | Development record |
| Captopril TabletsLP-049 | TabletMedicine | 12.5 mg; 25 mg; 50 mg | Blister 10 x 10 tablets | Development record |
| Clopidogrel TabletsLP-050 | TabletMedicine | 75 mg | Blister 10 x 10 tablets | Development record |
| Enalapril TabletsLP-051 | TabletMedicine | 5 mg; 10 mg; 20 mg | Blister 10 x 10 tablets | Development record |
| Furosemide TabletsLP-052 | TabletMedicine | 20 mg; 40 mg | Blister 10 x 10 tablets | Development record |
| Hydrochlorothiazide TabletsLP-053 | TabletMedicine | 12.5 mg; 25 mg; 50 mg | Blister 10 x 10 tablets | Development record |
| Losartan TabletsLP-054 | TabletMedicine | 50 mg; 100 mg | Blister 10 x 10 tablets | Development record |
| Nifedipine TabletsLP-055 | TabletMedicine | 10 mg immediate-release; 20 mg modified-release; 30 mg extended-release | Blister 10 x 10 tablets | Development record |
| Simvastatin TabletsLP-056 | TabletMedicine | 10 mg; 20 mg; 40 mg | Blister 10 x 10 tablets | Development record |
| Spironolactone TabletsLP-057 | TabletMedicine | 25 mg; 50 mg; 100 mg | Blister 10 x 10 tablets | Development record |
Dermatology Products13 public records
| Record | Dosage form / type | Proposed strength / configuration | Proposed pack | Status |
|---|---|---|---|---|
| Acyclovir CreamLP-087 | CreamMedicine | 5% | Tube 5 g / 10 g | Development record |
| Benzyl benzoate LotionLP-088 | LotionMedicine | 25% | Bottle 100 mL | Development record |
| Chlorhexidine SolutionLP-089 | SolutionMedicine | 0.05%; 4%; 5% concentrate | Bottle 100 mL / 500 mL | Development record |
| Clotrimazole CreamLP-090 | CreamMedicine | 1% | Tube 20 g / 30 g | Development record |
| Diclofenac sodium GelLP-091 | GelMedicine | 1%; 2% | Tube 20 g / 30 g | Development record |
| Fusidic acid CreamLP-098 | CreamMedicine | 2% | Tube 15 g | Development record |
| Hydrocortisone CreamLP-092 | CreamMedicine | 1%; 2.5% | Tube 15 g / 30 g | Development record |
| Miconazole CreamLP-093 | CreamMedicine | 2% | Tube 20 g / 30 g | Development record |
| Mupirocin OintmentLP-099 | OintmentMedicine | 2% | Tube 5 g / 15 g | Development record |
| Nystatin CreamLP-094 | CreamMedicine | 100,000 IU/g | Tube 15 g / 30 g | Development record |
| Permethrin CreamLP-095 | CreamMedicine | 5% | Tube 30 g / 60 g | Development record |
| Polyvidone iodine SolutionLP-096 | SolutionMedicine | 10% | Bottle 30 mL / 100 mL / 500 mL | Development record |
| Silver sulfadiazine CreamLP-097 | CreamMedicine | 1% | Tube 20 g / 50 g; jar 250 g for hospital | Development record |
Diabetes & Metabolic Medicines4 public records
| Record | Dosage form / type | Proposed strength / configuration | Proposed pack | Status |
|---|---|---|---|---|
| Glibenclamide TabletsLP-058 | TabletMedicine | 5 mg | Blister 10 x 10 tablets | Development record |
| Gliclazide TabletsLP-059 | TabletMedicine | 80 mg immediate-release; 30 mg modified-release; 60 mg modified-release | Blister 10 x 10 tablets | Development record |
| Glipizide TabletsLP-060 | TabletMedicine | 5 mg; 10 mg | Blister 10 x 10 tablets | Development record |
| Metformin TabletsLP-061 | TabletMedicine | 500 mg; 850 mg; 1000 mg | Blister 10 x 10 tablets | Development record |
Endocrinology & HRT1 public record
| Record | Dosage form / type | Proposed strength / configuration | Proposed pack | Status |
|---|---|---|---|---|
| Levothyroxine TabletsLP-119 | TabletMedicine | 25 mcg; 50 mcg; 75 mcg; 88 mcg; 100 mcg; 112 mcg; 125 mcg; 137 mcg; 150 mcg; 175 mcg; 200 mcg | Blister/bottle 30 or 100 tablets | Development record |
Essential Medicines2 public records
| Record | Dosage form / type | Proposed strength / configuration | Proposed pack | Status |
|---|---|---|---|---|
| Oral rehydration salts Sachet powderLP-001 | Sachet powderMedicine | WHO low-osmolarity sachet for 200 mL; WHO low-osmolarity sachet for 1 L | Sachet; carton 100 sachets | Development record |
| Paracetamol TabletsLP-002 | TabletMedicine | 500 mg; 650 mg | Blister 10 x 10 tablets; bottle 100 tablets | Development record |
Gastrointestinal Medicines13 public records
| Record | Dosage form / type | Proposed strength / configuration | Proposed pack | Status |
|---|---|---|---|---|
| Bisacodyl SuppositoriesLP-075 | SuppositoryMedicine | 10 mg | Strip/carton 10 units | Development record |
| Bisacodyl TabletsLP-076 | TabletMedicine | 5 mg | Blister 10 x 10 tablets | Development record |
| Domperidone Oral suspensionLP-005 | Oral suspensionMedicine | 1 mg/mL | Bottle 30 mL / 60 mL | Development record |
| Domperidone TabletsLP-077 | TabletMedicine | 10 mg | Blister 10 x 10 tablets | Development record |
| Famotidine TabletsLP-078 | TabletMedicine | 20 mg; 40 mg | Blister 10 x 10 tablets | Development record |
| Hyoscine butylbromide TabletsLP-079 | TabletMedicine | 10 mg | Blister 10 x 10 tablets | Development record |
| Lactulose SyrupLP-080 | SyrupMedicine | 3.35 g/5 mL | Bottle 100 mL / 200 mL | Development record |
| Loperamide CapsulesLP-081 | CapsuleMedicine | 2 mg | Blister 10 x 10 capsules | Development record |
| Metoclopramide TabletsLP-082 | TabletMedicine | 10 mg | Blister 10 x 10 tablets | Development record |
| Omeprazole CapsulesLP-083 | CapsuleMedicine | 10 mg; 20 mg; 40 mg | Blister 10 x 10 capsules | Development record |
| Ondansetron TabletsLP-084 | TabletMedicine | 4 mg; 8 mg | Blister 10 x 10 tablets | Development record |
| Pantoprazole TabletsLP-085 | TabletMedicine | 40 mg | Blister 10 x 10 tablets | Development record |
| Senna TabletsLP-086 | TabletMedicine | 7.5 mg sennosides; 8.6 mg sennosides | Blister/bottle | Development record |
Hospital Injectable Products33 public records
| Record | Dosage form / type | Proposed strength / configuration | Proposed pack | Status |
|---|---|---|---|---|
| Adrenaline InjectionLP-174 | InjectionMedicine | 1 mg/mL | Ampoule 1 mL; carton 10 ampoules | Development record |
| Ampicillin Powder for injectionLP-175 | Powder for injectionMedicine | 500 mg vial; 1 g vial | Vial; carton 10 vials | Development record |
| Atropine InjectionLP-176 | InjectionMedicine | 0.6 mg/mL | Ampoule 1 mL; carton 10 ampoules | Development record |
| Benzathine benzylpenicillin Powder for injectionLP-177 | Powder for injectionMedicine | 1.2 million IU vial; 2.4 million IU vial | Vial; carton 10 vials | Development record |
| Calcium folinate InjectionLP-178 | InjectionMedicine | 10 mg/mL ready-to-use solution; 50 mg per 5 mL vial (10 mg/mL) ready-to-use | Vial/ampoule; carton 10 | Development record |
| Cefazolin Powder for injectionLP-179 | Powder for injectionMedicine | 1 g vial; 2 g vial | Vial; carton 10 vials | Development record |
| Ceftriaxone Powder for injectionLP-180 | Powder for injectionMedicine | 500 mg vial; 1 g vial; 2 g vial | Vial; carton 10 vials | Development record |
| Cyanocobalamin (Vitamin B12) InjectionLP-181 | InjectionMedicine | 1000 mcg/mL | Ampoule 1 mL; carton 10 ampoules | Development record |
| Dexamethasone InjectionLP-182 | InjectionMedicine | 4 mg/mL | Ampoule 1 mL / 2 mL; carton 10 ampoules | Development record |
| Dextrose InjectionLP-183 | InjectionMedicine | 5% 500 mL IV infusion; 10% 500 mL IV infusion; 50% 50 mL ampoule | IV bottle/bag or ampoule | Development record |
| Diazepam InjectionLP-184 | InjectionMedicine | 5 mg/mL | Ampoule 2 mL; carton 10 ampoules | Development record |
| Furosemide InjectionLP-185 | InjectionMedicine | 10 mg/mL | Ampoule 2 mL; carton 10 ampoules | Development record |
| Gentamicin InjectionLP-186 | InjectionMedicine | 40 mg/mL (80 mg per 2 mL ampoule) | Ampoule 2 mL; carton 10 ampoules | Development record |
| Haloperidol InjectionLP-187 | InjectionMedicine | 5 mg/mL | Ampoule 1 mL; carton 10 ampoules | Development record |
| Heparin sodium InjectionLP-188 | InjectionMedicine | 5,000 IU/mL (25,000 IU per 5 mL vial) | Vial; carton 10 vials | Development record |
| Hydrocortisone Powder for injectionLP-189 | Powder for injectionMedicine | 100 mg vial | Vial; carton 10 vials | Development record |
| Hyoscine butylbromide InjectionLP-190 | InjectionMedicine | 20 mg/mL | Ampoule 1 mL; carton 10 ampoules | Development record |
| Insulin 30/70 InjectionLP-191 | InjectionMedicine | 100 IU/mL — 30% soluble human insulin with 70% isophane (NPH) human insulin; vial or cartridge | 10 mL vial or 3 mL cartridge; cold-chain carton | Development record |
| Insulin NPH InjectionLP-192 | InjectionMedicine | 100 IU/mL vial | 10 mL vial; cold-chain carton | Development record |
| Insulin soluble InjectionLP-193 | InjectionMedicine | 100 IU/mL vial | 10 mL vial; cold-chain carton | Development record |
| Lidocaine InjectionLP-194 | InjectionMedicine | 1%; 2% | Ampoule 2 mL / 5 mL / 10 mL | Development record |
| Magnesium sulfate InjectionLP-195 | InjectionMedicine | 500 mg/mL | Ampoule 10 mL; carton 10 ampoules | Development record |
| Metoclopramide InjectionLP-196 | InjectionMedicine | 5 mg/mL | Ampoule 2 mL; carton 10 ampoules | Development record |
| Ondansetron InjectionLP-197 | InjectionMedicine | 2 mg/mL | Ampoule 2 mL / 4 mL; carton 10 ampoules | Development record |
| Oxytocin InjectionLP-198 | InjectionMedicine | 10 IU/mL | Ampoule 1 mL; cold-chain carton | Development record |
| Phenytoin InjectionLP-199 | InjectionMedicine | 50 mg/mL | Ampoule 5 mL; carton 10 ampoules | Development record |
| Potassium chloride InjectionLP-200 | InjectionMedicine | 2 mEq/mL | Ampoule 10 mL; hospital use only | Development record |
| Sodium bicarbonate InjectionLP-201 | InjectionMedicine | 8.4% | Ampoule 10 mL / 20 mL | Development record |
| Sodium chloride InjectionLP-202 | InjectionMedicine | 0.9% 10 mL ampoule; 0.9% 500 mL IV infusion | Ampoule or IV bottle/bag | Development record |
| Thiamine (Vitamin B1) InjectionLP-203 | InjectionMedicine | 100 mg/mL | Ampoule 1 mL; carton 10 ampoules | Development record |
| Tranexamic acid InjectionLP-204 | InjectionMedicine | 100 mg/mL | Ampoule 5 mL; carton 10 ampoules | Development record |
| Vitamin K1 InjectionLP-205 | InjectionMedicine | 10 mg/mL | Ampoule 1 mL; carton 10 ampoules | Development record |
| Water for injection InjectionLP-206 | InjectionMedicine | 5 mL ampoule; 10 mL ampoule; 20 mL ampoule | Ampoule; carton 100 ampoules | Development record |
Medical Devices & Diagnostics10 public records
| Record | Dosage form / type | Proposed strength / configuration | Proposed pack | Status |
|---|---|---|---|---|
| Blood glucose test strips Diagnostic testLP-207 | Diagnostic testDevice / diagnostic | 25 strips; 50 strips | Vial/carton; supplied as a matched strip-and-meter system | Development record |
| Blood pressure monitor Medical deviceLP-208 | Medical deviceDevice / diagnostic | Automatic upper-arm device | Retail carton | Development record |
| COVID/Influenza antigen test Diagnostic testLP-209 | Diagnostic testDevice / diagnostic | Combo cassette | Single-use pouch; carton 20/25 | Development record |
| Digital thermometer Medical deviceLP-210 | Medical deviceDevice / diagnostic | Digital device | Retail carton | Development record |
| Glucometer Medical deviceLP-211 | Medical deviceDevice / diagnostic | Meter device | Retail carton with lancet device option | Development record |
| IV cannula Medical deviceLP-212 | Medical deviceDevice / diagnostic | 18G; 20G; 22G; 24G | Sterile single-use pack | Development record |
| Malaria rapid diagnostic test Diagnostic testLP-213 | Diagnostic testDevice / diagnostic | Pf/Pan cassette | Single-use pouch; carton 25 | Development record |
| Pregnancy rapid test Diagnostic testLP-214 | Diagnostic testDevice / diagnostic | Strip; Cassette; Midstream | Single-use pouch; carton 25/50 | Development record |
| Syringe Medical deviceLP-215 | Medical deviceDevice / diagnostic | 1 mL; 3 mL; 5 mL; 10 mL | Sterile single-use pack | Development record |
| Urine test strips Diagnostic testLP-216 | Diagnostic testDevice / diagnostic | 10-parameter strips; 11-parameter strips | Bottle 100 strips | Development record |
Neurology & Psychiatry10 public records
| Record | Dosage form / type | Proposed strength / configuration | Proposed pack | Status |
|---|---|---|---|---|
| Amitriptyline TabletsLP-152 | TabletMedicine | 10 mg; 25 mg | Blister 10 x 10 tablets | Development record |
| Carbamazepine TabletsLP-153 | TabletMedicine | 100 mg; 200 mg; 400 mg controlled-release | Blister 10 x 10 tablets | Development record |
| Diazepam TabletsLP-159 | TabletMedicine | 2 mg; 5 mg; 10 mg | Blister 10 x 10 tablets | Development record |
| Fluoxetine CapsulesLP-154 | CapsuleMedicine | 20 mg | Blister 10 x 10 capsules | Development record |
| Haloperidol TabletsLP-160 | TabletMedicine | 1.5 mg; 5 mg | Blister/bottle | Development record |
| Phenobarbital TabletsLP-161 | TabletMedicine | 30 mg; 60 mg; 100 mg | Blister/bottle | Development record |
| Phenytoin CapsulesLP-155 | CapsuleMedicine | 100 mg | Blister 10 x 10 capsules | Development record |
| Risperidone TabletsLP-156 | TabletMedicine | 1 mg; 2 mg; 4 mg | Blister 10 x 10 tablets | Development record |
| Sertraline TabletsLP-157 | TabletMedicine | 50 mg; 100 mg | Blister 10 x 10 tablets | Development record |
| Sodium valproate TabletsLP-158 | TabletMedicine | 200 mg; 500 mg | Blister/bottle | Development record |
OTC Products6 public records
| Record | Dosage form / type | Proposed strength / configuration | Proposed pack | Status |
|---|---|---|---|---|
| Aluminium hydroxide + Magnesium hydroxide Oral suspensionLP-217 | Oral suspensionMedicine | Al(OH)3 320 mg + Mg(OH)2 400 mg/5 mL | Bottle 120 mL / 200 mL | Development record |
| Cetirizine TabletsLP-218 | TabletMedicine | 10 mg | Blister 10 x 10 tablets | Development record |
| Chlorpheniramine maleate TabletsLP-219 | TabletMedicine | 4 mg | Blister 10 x 10 tablets | Development record |
| Diclofenac sodium TabletsLP-220 | TabletMedicine | 50 mg | Blister 10 x 10 tablets | Development record |
| Ibuprofen TabletsLP-221 | TabletMedicine | 200 mg; 400 mg | Blister 10 x 10 tablets | Development record |
| Loratadine TabletsLP-222 | TabletMedicine | 10 mg | Blister 10 x 10 tablets | Development record |
Oncology Supportive Care5 public records
| Record | Dosage form / type | Proposed strength / configuration | Proposed pack | Status |
|---|---|---|---|---|
| Allopurinol TabletsLP-162 | TabletMedicine | 100 mg; 300 mg | Blister 10 x 10 tablets | Development record |
| Dexamethasone TabletsLP-163 | TabletMedicine | 0.5 mg; 4 mg | Blister 10 x 10 tablets | Development record |
| Folinic acid TabletsLP-165 | TabletMedicine | 5 mg; 15 mg | Blister/bottle | Development record |
| Mesna InjectionLP-166 | InjectionMedicine | 100 mg/mL | Ampoule 4 mL / 10 mL | Development record |
| Prednisolone TabletsLP-164 | TabletMedicine | 5 mg; 20 mg | Blister 10 x 10 tablets | Development record |
Pediatrics16 public records
| Record | Dosage form / type | Proposed strength / configuration | Proposed pack | Status |
|---|---|---|---|---|
| Amoxicillin + clavulanic acid Powder for oral suspensionLP-014 | Powder for oral suspensionMedicine | 125 mg + 31.25 mg/5 mL; 250 mg + 62.5 mg/5 mL; 400 mg + 57 mg/5 mL | Bottle for reconstitution 60 mL / 100 mL | Development record |
| Amoxicillin Powder for oral suspensionLP-013 | Powder for oral suspensionMedicine | 125 mg/5 mL; 250 mg/5 mL; 400 mg/5 mL | Bottle for reconstitution 60 mL / 100 mL | Development record |
| Azithromycin Powder for oral suspensionLP-015 | Powder for oral suspensionMedicine | 200 mg/5 mL | Bottle for reconstitution 15 mL / 30 mL | Development record |
| Cefalexin Powder for oral suspensionLP-016 | Powder for oral suspensionMedicine | 125 mg/5 mL; 250 mg/5 mL | Bottle for reconstitution 60 mL | Development record |
| Cefixime Powder for oral suspensionLP-017 | Powder for oral suspensionMedicine | 100 mg/5 mL | Bottle for reconstitution 30 mL / 60 mL | Development record |
| Cetirizine SyrupLP-003 | SyrupMedicine | 5 mg/5 mL | Bottle 60 mL | Development record |
| Chlorpheniramine maleate SyrupLP-004 | SyrupMedicine | 2 mg/5 mL | Bottle 60 mL | Development record |
| Ibuprofen Oral suspensionLP-006 | Oral suspensionMedicine | 100 mg/5 mL | Bottle 60 mL / 100 mL | Development record |
| Metronidazole Oral suspensionLP-018 | Oral suspensionMedicine | 200 mg/5 mL | Bottle 60 mL / 100 mL | Development record |
| Multivitamin SyrupLP-007 | SyrupMedicine | Vitamins A, D, E, C, B1, B2, B3, B5, B6, B12; quantities to be confirmedUnresolved field: the exact value is not established. The record page shows the full catalogue wording. | Bottle 60 mL / 100 mL | Development record |
| Paracetamol SuppositoriesLP-008 | SuppositoryMedicine | 125 mg; 250 mg | Strip or blister; carton 10 units | Development record |
| Paracetamol SyrupLP-009 | SyrupMedicine | 120 mg/5 mL; 250 mg/5 mL | Bottle 60 mL / 100 mL | Development record |
| Salbutamol SyrupLP-010 | SyrupMedicine | 2 mg/5 mL | Bottle 60 mL / 100 mL | Development record |
| Sulfamethoxazole + Trimethoprim Oral suspensionLP-019 | Oral suspensionMedicine | 200 mg + 40 mg/5 mL | Bottle 60 mL / 100 mL | Development record |
| Zinc sulfate Dispersible tabletLP-011 | Dispersible tabletMedicine | 10 mg; 20 mg | Blister 10 x 10 dispersible tablets | Development record |
| Zinc sulfate SyrupLP-012 | SyrupMedicine | 10 mg per 5 mL | Bottle 60 mL / 100 mL | Development record |
Respiratory Medicines8 public records
| Record | Dosage form / type | Proposed strength / configuration | Proposed pack | Status |
|---|---|---|---|---|
| Beclometasone InhalerLP-067 | InhalerMedicine | 50 mcg/dose; 100 mcg/dose; 250 mcg/dose | Metered-dose inhaler | Development record |
| Budesonide InhalerLP-068 | InhalerMedicine | 100 mcg/dose; 200 mcg/dose | Metered-dose inhaler | Development record |
| Budesonide Nebulizer solutionLP-069 | Nebulizer solutionMedicine | 0.25 mg/2 mL; 0.5 mg/2 mL | Unit-dose nebules; carton 20 | Development record |
| Ipratropium bromide InhalerLP-070 | InhalerMedicine | 20 mcg/dose | 200-dose metered-dose inhaler | Development record |
| Ipratropium bromide Nebulizer solutionLP-071 | Nebulizer solutionMedicine | 250 mcg/mL | Unit-dose nebules; carton 20 | Development record |
| Montelukast TabletsLP-066 | TabletMedicine | 4 mg chewable; 5 mg chewable; 10 mg | Blister 3 x 10 tablets | Development record |
| Salbutamol InhalerLP-072 | InhalerMedicine | 100 mcg/dose | 200-dose metered-dose inhaler | Development record |
| Salbutamol Nebulizer solutionLP-073 | Nebulizer solutionMedicine | 2.5 mg/2.5 mL; 5 mg/2.5 mL | Unit-dose nebules; carton 20 | Development record |
Vitamins & Nutrition7 public records
| Record | Dosage form / type | Proposed strength / configuration | Proposed pack | Status |
|---|---|---|---|---|
| Ascorbic acid (Vitamin C) TabletsLP-167 | TabletMedicine | 100 mg; 500 mg; 1000 mg | Blister/bottle | Development record |
| Calcium + Vitamin D3 TabletsLP-168 | TabletMedicine | Calcium carbonate providing 500 mg elemental calcium + 400 IU D3; calcium carbonate providing 600 mg elemental calcium + 400 IU D3 | Blister/bottle | Development record |
| Cyanocobalamin (Vitamin B12) TabletsLP-169 | TabletMedicine | 1000 mcg | Blister/bottle | Development record |
| Pyridoxine (Vitamin B6) TabletsLP-170 | TabletMedicine | 25 mg; 50 mg | Blister/bottle | Development record |
| Retinol (Vitamin A) CapsulesLP-171 | CapsuleMedicine | 100,000 IU; 200,000 IU | Soft capsule; bottle or blister | Development record |
| Retinol (Vitamin A) Oral dropsLP-172 | Oral dropsMedicine | 50,000 IU/mL | Dropper bottle | Development record |
| Thiamine (Vitamin B1) TabletsLP-173 | TabletMedicine | 100 mg | Blister/bottle | Development record |
Women's Health11 public records
| Record | Dosage form / type | Proposed strength / configuration | Proposed pack | Status |
|---|---|---|---|---|
| Clotrimazole Vaginal tabletLP-100 | Vaginal tabletMedicine | 100 mg; 200 mg; 500 mg | Blister; single or 6-tablet pack | Development record |
| Ethinylestradiol + levonorgestrel Tablet cycle packLP-101 | Tablet cycle packMedicine | 30 mcg + 150 mcg; 30 mcg + 250 mcg | 21/28-tablet cycle pack | Development record |
| Ferrous sulfate + folic acid TabletsLP-102 | TabletMedicine | Ferrous sulfate equivalent to 60 mg elemental iron + 400 mcg folic acid | Blister 10 x 10 tablets; bottle 1000 for programs | Development record |
| Folic acid TabletsLP-103 | TabletMedicine | 400 mcg; 1 mg; 5 mg | Blister 10 x 10 tablets | Development record |
| Levonorgestrel Progestin-only tabletLP-224 | Progestin-only tabletMedicine | 30 mcg | 28-tablet cycle pack | Development record |
| Levonorgestrel TabletsLP-104 | TabletMedicine | 1.5 mg single tablet; 750 mcg x 2 tablets | Blister; emergency pack | Development record |
| Medroxyprogesterone acetate InjectionLP-108 | InjectionMedicine | 150 mg/mL vial; 104 mg/0.65 mL prefilled device | Vial or prefilled device; storage to be confirmedUnresolved field: the exact value is not established. The record page shows the full catalogue wording. | Development record |
| Methyldopa TabletsLP-105 | TabletMedicine | 250 mg | Blister 10 x 10 tablets | Development record |
| Misoprostol TabletsLP-109 | TabletMedicine | 200 mcg | Blister 4 or 10 tablets | Development record |
| Norethisterone TabletsLP-106 | TabletMedicine | 5 mg; 350 mcg | 5 mg: blister 10 x 10 tablets; 350 mcg: 28-tablet cycle pack | Development record |
| Tranexamic acid TabletsLP-107 | TabletMedicine | 250 mg; 500 mg | Blister 10 x 10 tablets | Development record |
No matching record.
Try a broader generic name, another presentation or a portfolio reference.
03 · Status definitions
Read the evidence before drawing a conclusion.
| Label | Meaning | Does not establish |
|---|---|---|
| Development record | A controlled public catalogue identity | Registration, manufacture or supply |
| Proposed presentation | A source-recorded form, strength or pack | Approved specification or exact pack mapping |
| Planned capability | A future manufacturing or service interest | An installed line or an available service |
| Archived source review | An earlier editorial examination of sources | Current medical or regulatory approval |
04 · Related evidence
A record belongs in a wider context.
| Evidence route | What it covers |
|---|---|
| Initial manufacturing scope | The two planned modules documented in the June 2026 project brief |
| Quality evidence framework | Why evidence is tied to the exact product |
| Planned capabilities | Every catalogue entry marked Planned |
Professional enquiries
Ask about an exact portfolio record.
Include the public reference, proposed presentation, destination and the evidence required. A technical discussion does not establish supply availability.